Decompensated MASH-cirrhosis model by acute and toxic effects of phenobarbital.

dc.contributor.author
Grünewald, Inga
dc.contributor.author
Kraus, Nico
dc.contributor.author
Uschner, Frank Erhard
dc.contributor.author
Moeslein, Magnus
dc.contributor.author
Schierwagen, Robert
dc.contributor.author
Gu, Wenyi
dc.contributor.author
Brol, Maximilian Joseph
dc.contributor.author
Fürst, Eike
dc.contributor.author
Lotersztajn, Sophie
dc.contributor.author
Rautou, Pierre-Emmanuel
dc.contributor.author
Duran Güell, Marta
dc.contributor.author
Flores Costa, Roger
dc.contributor.author
Clària i Enrich, Joan
dc.contributor.author
Trebicka, Jonel
dc.contributor.author
Klein, Sabine
dc.date.issued
2025-04-07T08:19:08Z
dc.date.issued
2025-04-07T08:19:08Z
dc.date.issued
2024
dc.date.issued
2025-04-07T08:19:08Z
dc.identifier
2073-4409
dc.identifier
https://hdl.handle.net/2445/220281
dc.identifier
756642
dc.identifier
39451225
dc.description.abstract
Metabolic dysfunction-associated Steatohepatitis (MASH), is a prominent cause for liver cirrhosis. MASH-cirrhosis is responsible for liver complications and there is no specific treatment. To develop new therapeutic approaches, animal models are needed. The aim of this study was to develop a fast animal model of MASH-cirrhosis in rats reflecting the human disease. Carbon tetrachloride (CCl4) injections in combination with a high-fat Western diet (WD) were used to induce MASH-cirrhosis. To accelerate liver injury, animals received phenobarbital (PB) in their drinking water using two different regimens. Rats developed advanced MASH-cirrhosis characterized by portal hypertension, blood biochemistry, hepatic ballooning, steatosis, inflammation and fibrosis. Importantly, rats receiving low-dose PB for the long term (LT) showed ascites after 6 weeks, whereas rats with high-dose short-term (ST) PB developed ascites after 8 weeks. ST- and LT-treated rats showed increased portal pressure (PP) and decreased mean arterial pressure (MAP). Of note, hepatocyte ballooning was only observed in the LT group. The LT administration of low-dose PB with CCl4 intoxication and WD represents a fast and reproducible rat model mimicking decompensated MASH-cirrhosis in humans. Thus, CCl4 + WD with LT low-dose phenobarbital treatment might be the preferred rat animal model for drug development in MASH-cirrhosis.
dc.format
16 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
MDPI
dc.relation
Reproducció del document publicat a: https://doi.org/10.3390/cells13201707
dc.relation
Cells, 2024, vol. 13, num.20
dc.relation
https://doi.org/10.3390/cells13201707
dc.rights
cc-by (c) Kraus N et al., 2024
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Biomedicina)
dc.subject
Malalties del fetge
dc.subject
Hipercolesterolèmia
dc.subject
Cirrosi hepàtica
dc.subject
Liver diseases
dc.subject
Hypercholesteremia
dc.subject
Hepatic cirrhosis
dc.title
Decompensated MASH-cirrhosis model by acute and toxic effects of phenobarbital.
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Files in this item

FilesSizeFormatView

There are no files associated with this item.